Overview
Mucinex® for Treatment of Filamentary Keratitis
Status:
Completed
Completed
Trial end date:
2018-07-01
2018-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Massachusetts Eye and Ear InfirmaryTreatments:
Chlorpheniramine, phenylpropanolamine drug combination
Guaifenesin
Phenylpropanolamine
Criteria
Inclusion Criteria:- Patients with filamentary keratitis
- 18 years and older
Exclusion Criteria:
- Active ocular surface infection of any type
- Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been
associated in rare cases of development of kidney stones
- Schirmer's test<3mm
- History of hypersensitivity to Mucinex®
- Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical
steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.